Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

tunlametinib (HL-085)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Tianjin Binjiang Pharma

Drug class:

MEK inhibitor, MEK1 inhibitor, MEK2 inhibitor

Related drugs:

‹

›

NRAS mutation	Melanoma	NRAS mutation	Melanoma	HL-085 Sensitive: C2 – Inclusion Criteria HL-085 Sensitive : C2	HL-085 Sensitive: C2 – Inclusion Criteria HL-085 Sensitive : C2
NRAS Q61	Melanoma	NRAS Q61	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS G13R	Melanoma	NRAS G13R	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS Q61L	Melanoma	NRAS Q61L	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS G12D	Melanoma	NRAS G12D	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS G12S	Melanoma	NRAS G12S	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3
BRAF V600	Non Small Cell Lung Cancer	BRAF V600	Non Small Cell Lung Cancer	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3
BRAF V600	Pancreatic Ductal Adenocarcinoma	BRAF V600	Pancreatic Ductal Adenocarcinoma	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3